Clinical trials for medicines: Clinical Trials Regulations transitional arrangements

AI Summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has finalized guidance for the transition to the amended Medicines for Human Use (Clinical Trials) Regulations, effective April 28, 2026. This regulatory framework establishes distinct requirements for trials submitted before the deadline (‘old rules’) versus those submitted on or after (‘new rules’). The primary compliance focus involves transparency, safety reporting, and product labeling updates. For trials ending on or after the effective date, sponsors must ensure public registration and results publication within specified timeframes. While older trials maintain some previous approval standards, they must adopt updated Good Clinical Practice and manufacturing protocols. Required actions for sponsors include auditing existing portfolios to ensure all investigational products manufactured after the deadline meet new labeling standards. Non-investigational products require even earlier action, with labeling amendments due 35 days prior to the transition. Additionally, sponsors must transition to new pharmacovigilance reporting systems, although a temporary reprieve is available until the first annual safety report post-transition. Failure to comply with these updated requirements will trigger enforcement measures under the 2025 amended regulations. Organizations are encouraged to perform risk assessments on labeling changes to determine if substantial modifications require formal regulatory approval before implementation.